Adia Nutrition Inc (ADIA) 주가 예측

Adia Nutrition, Inc. is engaged in the creation of probiotics. The company is headquartered in Winter Park, Florida. The company went IPO on 2004-03-23. The Company’s divisions include supplement division and medical division. The supplement division provides organic supplements. The medical division establishes clinics that specialize in stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Adia Med of Winter Park, LLC, its subsidiary, operates clinic to perform treatments, and Adia Labs, LLC, its subsidiary, procures and sells the products relating to these procedures. Adia Med is conducting a nationwide rollout of satellite locations offering Umbilical Cord Stem Cell (UCB-SC) and exosome treatments, like AdiaVita from Adia Labs LLC, with at least 100 million stem cells and three trillion exosomes per unit. These therapies address chronic inflammation, autoimmune disorders, and orthopedic issues. The firm has approximately 18% equity position in Cement Factory, LLC.